Clinical Trials Logo

Infections clinical trials

View clinical trials related to Infections.

Filter by:

NCT ID: NCT06172010 Recruiting - Clinical trials for Prosthetic-joint Infection

Rifampicin Combination Therapy Versus Monotherapy for Staphylococcal Prosthetic Joint Infection

RiCOTTA
Start date: April 1, 2023
Phase: Phase 4
Study type: Interventional

In this Dutch multicenter clinical trial, patients with a staphylococcal prosthetic joint infection, will, in the oral antibiotic treatment phase, be randomized between clindamycin monotherapy and rifampicin / levofloxacin combination therapy. The clinical endpoint will be treatment success one year after finishing antimicrobial treatment.

NCT ID: NCT06170242 Recruiting - RSV Infection Clinical Trials

A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model

Start date: November 20, 2023
Phase: Phase 2
Study type: Interventional

A randomized, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-323 in healthy subjects infected with RSV-A Memphis 37b. This study is designed to assess the antiviral effect of EDP-323 compared to a placebo control in the respiratory syncytial virus challenge model.

NCT ID: NCT06169553 Not yet recruiting - Infections Clinical Trials

The Injection-Related InfectionS (IRIS) Program

IRIS
Start date: January 2024
Phase: N/A
Study type: Interventional

People who inject drugs are at risk of injection-related infections, like abscesses or infective endocarditis. The Injection-Related InfectionS (IRIS) program hopes to improve treatment for participants by providing a low-barrier, one-stop shop model for people who inject drugs who experience injection-related infections to access more holistic and compassionate care. IRIS is a non-randomized clinical trial, meaning that it offers a specific program to eligible patients. This program offers care for substance use and infectious disease with additional peer support and systems navigation, if interested. The investigators anticipate enrolling 80 participants in the intervention and will follow participants throughout the infection treatment period (estimated 6-12 weeks). The investigators will collect information at the time of enrolment, at the 6-month mark, and monthly via electronic medical chart review. The investigators will use an interrupted time series analysis to evaluate the impact of the intervention on rates of treatment completion, emergency department visits, hospitalizations, and death, before versus after the intervention.

NCT ID: NCT06168708 Recruiting - Clinical trials for Post-TURP Infectious Complications

The Safety and Efficacy of Addition of Gentamicin on Irrigation Fluid in Prevention of Post-Transurethral Resection of the Prostate Infectious Complications.

Start date: December 7, 2023
Phase: N/A
Study type: Interventional

The aim of this clinical study is to evaluate the safety and efficacy of addition of gentamicin on irrigation fluid during trans-urethral resection of the prostate (TURP) and its role in reduction of post-TURP infectious complications. the participants will be randomly divided into two groups: Group A (gentamicin group) and group B (Placebo).

NCT ID: NCT06168448 Not yet recruiting - Infectious Disease Clinical Trials

Contribution of a Video Support to Inform the Patient Before a Complementary Examination in Infectious Diseases

AVIEMI
Start date: December 2023
Phase:
Study type: Observational

The purpose of this study is that a video tool coupled with standardized information can increase the patient's understanding of the information and thus optimize their medical care

NCT ID: NCT06167616 Completed - Type 2 Diabetes Clinical Trials

Infections and Latent Autoimmune Diabetes in Adults

LADA
Start date: September 1, 2010
Phase:
Study type: Observational [Patient Registry]

Infections are proposed risk factors for type 1 diabetes in children. The investigators will examine whether a diagnosis of infectious disease also confers an increased risk of latent autoimmune diabetes in adults.

NCT ID: NCT06167083 Active, not recruiting - Clinical trials for Carbapenem Resistant Bacterial Infection

Machine Learning in the ICU: Predicting Mortality in Bloodstream Infections (ICU:Intensive Care Unit)

ICU
Start date: April 12, 2024
Phase:
Study type: Observational

Using our own patient data, our study aimed to predict mortality that can develop in Carbapenem-resistant Gram-negative bacilli bloodstream infections with a machine learning-based model. In the intensive care unit, patients with bloodstream infections, both with and without mortality, will be examined retrospectively in two subgroups for comparison.

NCT ID: NCT06166979 Not yet recruiting - Clinical trials for Microbial Colonization

Colonisation of Scalp by Topical Probiotic Micrococcus Luteus Q24

Start date: January 15, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the skin quality improvement and colonization efficacy following the application of probiotic Micrococcus luteus Q24 (BLIS Q24) to the scalp from a serum format in healthy adults.

NCT ID: NCT06166381 Not yet recruiting - Clinical trials for Infection, Bacterial

Parenteral Versus Combined Parenteral With Vancomycin-soaked Graft in ACL Reconstruction

Start date: January 25, 2024
Phase: N/A
Study type: Interventional

An anterior cruciate ligament (ACL) tear is one of the knee joint's most common soft tissue injuries [1]. It is frequently injured in non-contact and some contact competition sports and even during ordinary life activities. With an annual incidence of 68.6 per 100,000 person-years, ACL tears remain a common orthopedic injury [2]. Females are two to eight times more likely to develop ACL tears in sports compared to men who play the same particular sports [3]. Most highly demanding persons and those who develop frequent instability of their knee require reconstructive surgery on the ACL to prevent early degenerative changes in their knees. This is done by completely removing the torn or ruptured ACL and replacement with a piece of tendon or ligament (graft) [4]. Post-operative infection may occur in 0.14-2.6% of ACL reconstruction despite intravenous antibiotics prophylaxis [5,6]. The deep infection results in poor outcomes with pain, stiffness, arthrofibrosis, and articular cartilage degeneration [7,8]. Few studies reported improved outcomes of infection control when the autograft presoaked in vancomycin solution during the preparation process outside the body before being transferred to the knee of the patient [9-13]. Systematic reviews and meta-analysis showed that all the articles discussing the outcome of vancomycin presoaked autograft in ACL reconstruction surgery were case series, observational retrospective, prospective comparative, or case-control studies [14,15]. Randomized control trial (RCT) provides the strongest evidence among the primary research studies to confirm the effectiveness of a new method of treatment [16,17]. To date, there is no available RCT study in this field.

NCT ID: NCT06164600 Recruiting - Clinical trials for Urinary Tract Infections

Bovine Colostrum for Prophylaxis Against Recurrent Urinary Tract Infection in Children

Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

Prebiotics as bovine colostrum are considered as a valuable supplement in the prevention of upper respiratory tract infections, gastrointestinal tract infections and neonatal sepsis. It contains many bioactive substances, such as immunoglobulins, lactoferrin, lysozyme, lactoperoxidase, and other growth factors.There is a lack of research on the use of prebiotics for prophylaxis against recurrent urinary tract infection (UTI) in children.In this era of increasing bacterial resistance to antimicrobial therapy, bovine colostrum can offer an approach for prophylaxis against UTI in these patients.We aim at this trial to evaluate the efficacy and safety of bovine colostrum as a prebiotic for prophylaxis against recurrent urinary tract infection in children.